PL2281032T3 - Komórki TR1 do leczenia stanu artretycznego - Google Patents
Komórki TR1 do leczenia stanu artretycznegoInfo
- Publication number
- PL2281032T3 PL2281032T3 PL09737985T PL09737985T PL2281032T3 PL 2281032 T3 PL2281032 T3 PL 2281032T3 PL 09737985 T PL09737985 T PL 09737985T PL 09737985 T PL09737985 T PL 09737985T PL 2281032 T3 PL2281032 T3 PL 2281032T3
- Authority
- PL
- Poland
- Prior art keywords
- arthritis
- cells
- treatment
- Prior art date
Links
- 206010003246 arthritis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4830908P | 2008-04-28 | 2008-04-28 | |
| EP08305133A EP2113560A1 (en) | 2008-04-28 | 2008-04-28 | Compositions for treating an arthritic condition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2281032T3 true PL2281032T3 (pl) | 2017-01-31 |
Family
ID=39535829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09737985T PL2281032T3 (pl) | 2008-04-28 | 2009-04-08 | Komórki TR1 do leczenia stanu artretycznego |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20110038844A1 (pl) |
| EP (3) | EP2113560A1 (pl) |
| JP (2) | JP6111014B2 (pl) |
| KR (2) | KR20160093090A (pl) |
| CN (2) | CN108159407A (pl) |
| AU (1) | AU2009242299B2 (pl) |
| BR (1) | BRPI0911580A2 (pl) |
| CA (1) | CA2722816C (pl) |
| DK (1) | DK2281032T3 (pl) |
| ES (1) | ES2599305T3 (pl) |
| HR (1) | HRP20161221T1 (pl) |
| HU (1) | HUE034048T2 (pl) |
| LT (1) | LT2281032T (pl) |
| PL (1) | PL2281032T3 (pl) |
| PT (1) | PT2281032T (pl) |
| RU (1) | RU2563360C2 (pl) |
| SI (1) | SI2281032T1 (pl) |
| WO (1) | WO2009132941A1 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2378287A1 (en) * | 2010-04-15 | 2011-10-19 | TXCell | New method for isolating Tr1 cells |
| NZ703122A (en) * | 2010-10-11 | 2016-06-24 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| WO2013105707A1 (ko) * | 2012-01-13 | 2013-07-18 | 가톨릭대학교 산학협력단 | 시트룰린화된 단백질에 특이적인 단클론 항체 및 이를 생산하는 하이브리도마 세포주 |
| US20140322188A1 (en) * | 2013-04-26 | 2014-10-30 | Enzo Biochem, Inc. | Tolerizing treatments for autoimmune disease |
| US20170232084A1 (en) | 2013-04-26 | 2017-08-17 | Enzo Biochem Inc. | Immune modulation for the treatment of age-related macular degeneration |
| AR097570A1 (es) * | 2013-09-06 | 2016-03-23 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | Composiciones y métodos para incrementar la migración de células mesenquimales del estroma hacia tumores |
| CN107456454A (zh) * | 2016-06-06 | 2017-12-12 | 先声药业有限公司 | 一种预防或治疗炎性疾病的药物组合物 |
| CN107670020B (zh) * | 2016-08-02 | 2020-09-18 | 富比积生物科技股份有限公司 | 四胜肽gekg在治疗退化性关节炎中的用途 |
| CN107670021B (zh) * | 2016-08-02 | 2020-09-18 | 富比积生物科技股份有限公司 | 五胜肽kttks在治疗退化性关节炎中的用途 |
| MX2024003409A (es) * | 2021-09-21 | 2024-04-05 | Univ Monash | Metodos de tratamiento. |
| WO2025059634A1 (en) * | 2023-09-15 | 2025-03-20 | The Regents Of The University Of California | Immunomodulatory nanoparticles for modulating arthritis flares |
| CN119925562B (zh) * | 2023-11-03 | 2025-11-28 | 中国科学院上海药物研究所 | 趋化因子受体2拮抗剂在制备治疗糖尿病并发焦虑症的应用 |
| CN118772295B (zh) * | 2024-08-15 | 2025-04-01 | 广州星银化妆品有限公司 | 一种淡斑多肽、含多肽的组合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO110397B1 (ro) * | 1989-03-21 | 1996-01-30 | Immune Response Corp San Diego | Vaccin pentru prevenirea sau tratarea unor boli care rezulta din raspunsuri patogene, prin populatii de celule t specifice, procedeu de obtinere si metode de diagnostic si tratament cu acesta |
| CA2117492C (en) * | 1992-02-28 | 2009-04-07 | Howard L. Weiner | Bystander suppression of autoimmune diseases |
| US6746670B2 (en) | 2000-08-15 | 2004-06-08 | Schering Corporation | Regulatory T cells; methods |
| FR2824567B1 (fr) | 2001-05-11 | 2003-08-08 | Inst Nat Sante Rech Med | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene |
| FR2856700B1 (fr) | 2003-06-24 | 2007-06-08 | Txcell | Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications |
| CA2575689C (en) * | 2004-08-11 | 2013-04-02 | Txcell | Tr1 cells for use in atherosclerosis |
| EP1712615A1 (en) | 2005-04-15 | 2006-10-18 | Txcell | In vitro production of a cell population using feeder cells |
| DK1739166T3 (da) | 2005-07-01 | 2011-10-10 | Txcell S A | Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population |
-
2008
- 2008-04-28 EP EP08305133A patent/EP2113560A1/en not_active Withdrawn
-
2009
- 2009-04-08 CN CN201810049613.2A patent/CN108159407A/zh active Pending
- 2009-04-08 CN CN2009801248321A patent/CN102076845A/zh active Pending
- 2009-04-08 US US12/989,857 patent/US20110038844A1/en not_active Abandoned
- 2009-04-08 ES ES09737985.3T patent/ES2599305T3/es active Active
- 2009-04-08 EP EP16178706.4A patent/EP3130666A1/en not_active Withdrawn
- 2009-04-08 HR HRP20161221TT patent/HRP20161221T1/hr unknown
- 2009-04-08 KR KR1020167020300A patent/KR20160093090A/ko not_active Ceased
- 2009-04-08 RU RU2010148464/10A patent/RU2563360C2/ru not_active IP Right Cessation
- 2009-04-08 PT PT97379853T patent/PT2281032T/pt unknown
- 2009-04-08 SI SI200931525A patent/SI2281032T1/sl unknown
- 2009-04-08 JP JP2011505459A patent/JP6111014B2/ja not_active Expired - Fee Related
- 2009-04-08 LT LTEP09737985.3T patent/LT2281032T/lt unknown
- 2009-04-08 PL PL09737985T patent/PL2281032T3/pl unknown
- 2009-04-08 CA CA2722816A patent/CA2722816C/en not_active Expired - Fee Related
- 2009-04-08 HU HUE09737985A patent/HUE034048T2/en unknown
- 2009-04-08 AU AU2009242299A patent/AU2009242299B2/en not_active Ceased
- 2009-04-08 BR BRPI0911580A patent/BRPI0911580A2/pt not_active IP Right Cessation
- 2009-04-08 EP EP09737985.3A patent/EP2281032B1/en not_active Not-in-force
- 2009-04-08 WO PCT/EP2009/054242 patent/WO2009132941A1/en not_active Ceased
- 2009-04-08 KR KR1020107026821A patent/KR101747902B1/ko not_active Expired - Fee Related
- 2009-04-08 DK DK09737985.3T patent/DK2281032T3/en active
-
2014
- 2014-08-08 JP JP2014162466A patent/JP2015007079A/ja not_active Ceased
-
2018
- 2018-05-15 US US15/980,337 patent/US20180250372A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009132941A1 (en) | 2009-11-05 |
| KR101747902B1 (ko) | 2017-06-16 |
| HUE034048T2 (en) | 2018-01-29 |
| US20180250372A1 (en) | 2018-09-06 |
| CA2722816A1 (en) | 2009-11-05 |
| RU2010148464A (ru) | 2012-06-10 |
| JP2015007079A (ja) | 2015-01-15 |
| JP6111014B2 (ja) | 2017-04-05 |
| PT2281032T (pt) | 2016-11-11 |
| CN102076845A (zh) | 2011-05-25 |
| SI2281032T1 (sl) | 2017-01-31 |
| DK2281032T3 (en) | 2016-10-10 |
| ES2599305T3 (es) | 2017-02-01 |
| CA2722816C (en) | 2018-01-09 |
| EP2281032A1 (en) | 2011-02-09 |
| HRP20161221T1 (hr) | 2017-01-13 |
| JP2011518797A (ja) | 2011-06-30 |
| KR20110017373A (ko) | 2011-02-21 |
| EP3130666A1 (en) | 2017-02-15 |
| RU2563360C2 (ru) | 2015-09-20 |
| BRPI0911580A2 (pt) | 2017-05-23 |
| KR20160093090A (ko) | 2016-08-05 |
| US20110038844A1 (en) | 2011-02-17 |
| EP2113560A1 (en) | 2009-11-04 |
| LT2281032T (lt) | 2016-11-25 |
| AU2009242299A1 (en) | 2009-11-05 |
| AU2009242299B2 (en) | 2015-05-14 |
| CN108159407A (zh) | 2018-06-15 |
| EP2281032B1 (en) | 2016-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2281032T3 (pl) | Komórki TR1 do leczenia stanu artretycznego | |
| EP2134446A4 (en) | BIOGAS PROCESSING | |
| PL2190883T3 (pl) | Sposób obróbki biomasy | |
| SMAP200900085A (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative | |
| BRPI0823297A2 (pt) | Garrafa | |
| EP2339910A4 (en) | GLASSHOUSE | |
| LT2313364T (lt) | Simetrinio dimetilarginino nustatymo būdai | |
| BRPI0821652A2 (pt) | tratamento de biocombustíveis | |
| DK2173831T3 (da) | Brøndbehandling | |
| FR2944062B1 (fr) | Injecteur d'ergols | |
| IT1393443B1 (it) | Stiratoio bitesta | |
| FI20105881L (fi) | Hydrosykloni | |
| DK2346661T3 (da) | Dannelsesfremgangsmåder | |
| DE502007002429D1 (de) | Endreaktor | |
| EP2169142A4 (en) | METHOD FOR MANUFACTURING FLOOR | |
| FR2937940B1 (fr) | Automotrice de transport de voyageurs | |
| FI20085583L (fi) | Ratkaisu meesan käsittelemiseksi | |
| HRP20160577T1 (hr) | Liječenje osteoartritisa | |
| EP2300594A4 (en) | ELECTROBIOCHEMICAL REACTOR | |
| EP2256754A4 (en) | REACTOR | |
| BRPI1013017A2 (pt) | "17beta-alquil-17alfa-óxi-estratrienos" | |
| FI20070190L (fi) | Bioreaktori | |
| EP2493665A4 (en) | MULTISELECTIVE MICROMANIPULATOR | |
| IT1398148B1 (it) | "auto-negozio" | |
| UA19919S (uk) | Цеглина пряма |